The parcel is not the end of care.

Find out who answers after the prescription

FDA, the U.S. Food and Drug Administration, identifies a warning sign after weight-medicine delivery: no licensed doctor whom patients can question.

Ask how to reach the care service and when to expect a reply.

Ask what a review visit would cover and whether it adds a charge.

• Who do I ask about a change in how I feel?
• Who handles a question about the label?
• What happens if the medicine does not meet the agreed goal?
• How is the next review arranged?
• Who helps if I need an in-person exam?

Resolve label and storage questions with the pharmacy

Check storage for the particular peptide product: refrigeration is needed for some, while room temperature suits others.

The product label and pharmacy instructions determine its storage needs.

Ask the pharmacist to explain any wording that is unclear.

Some weight and diabetes medicines act like GLP-1, a natural signal in the body that affects appetite and blood sugar.

In its information checked in September 2026, FDA advises against using an injectable GLP-1 medicine that arrives warm or without enough refrigeration.

Know when to seek urgent help

U.S. National Library of Medicine runs MedlinePlus, a health information service. It describes severe allergic reactions as emergencies with a threat to life.

Breathing difficulty and a swollen tongue or face are among the symptoms it lists.

MedlinePlus tells people with severe symptoms to seek emergency assistance or head to their nearest emergency room.

Through MedWatch, FDA’s programme for reporting product problems, patients can report problems with medicines too.